Axsome Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AXSM research report →
About the company
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression.
- CEO
- Herriot Tabuteau
- IPO
- 2015
- Employees
- 712
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $12.57B
- P/E
- -66.43
- P/S
- 17.75
- P/B
- 229.14
- EV/EBITDA
- -72.30
- Div Yield
- 0.00%
- Gross Margin
- 92.60%
- Op Margin
- -24.80%
- Net Margin
- -26.59%
- ROE
- -260.01%
- ROIC
- -50.29%
- Revenue
- $638.50M · 65.55%
- Net Income
- $-183,174,000 · 36.22%
- EPS
- $-3.68 · 38.56%
- Op Income
- $-169,235,000
- FCF YoY
- 27.04%
- 52W High
- $260.19
- 52W Low
- $96.09
- 50D MA
- $228.60
- 200D MA
- $173.47
- Beta
- 0.60
- Avg Volume
- 902.82K
Get TickerSpark's AI analysis on AXSM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | TABUTEAU HERRIOT | other | 49,666 |
| Jul 1, 26 | TABUTEAU HERRIOT | other | 49,666 |
| Jul 1, 26 | TABUTEAU HERRIOT | sell | 49,666 |
| Jun 10, 26 | JEFFS ROGER | sell | 286 |
| Jun 11, 26 | JEFFS ROGER | sell | 286 |
| Jun 8, 26 | JEFFS ROGER | other | 1,429 |
| Jun 8, 26 | JEFFS ROGER | other | 1,429 |
| Jun 8, 26 | Saad Mark E | other | 1,429 |
| Jun 8, 26 | Saad Mark E | other | 1,429 |
| Jun 8, 26 | Mahony Susan | other | 1,429 |
Our AXSM coverage
Recent articles, reports, and earnings notes.
Axsome Therapeutics (AXSM): AUVELITY Drives a Premium Growth Story
Axsome has evolved into a commercial CNS growth story, led by AUVELITY’s rapid prescription gains and a newly expanded Alzheimer’s agitation opportunity. The stock looks attractive on execution, but valuation and ongoing losses keep it from being a low-risk idea.
Best biotech stocks for May 2026
These seven biotech stocks stand out for commercial strength, earnings quality, and pipeline depth, with Amgen leading this May 2026 ranking.
Axsome Therapeutics, Inc. (AXSM) climbs on FDA win
Axsome Therapeutics, Inc. (AXSM) climbs after an FDA approval expanded AUVELITY into Alzheimer’s disease agitation, while Q1 2026 revenue jumped 57% year over year. Heavy volume, new highs, and higher analyst targets underscore the market’s growing confidence in Axsome’s commercial momentum.
Want a deeper read on AXSM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.